Epilepsy is one of the commonest of the serious neurological disorders. The total economic burden of epilepsy in the United Kingdom has been estimated to be £1930 m, with around £32 m spent on antiepileptic drug therapy alone. Despite the high level of expenditure on drug therapy for epilepsy there is very little information regarding the relative cost-effectiveness of the different drugs available. It is important to establish the relative cost-effectiveness of therapies to provide decision makers with the information necessary to allocate resources in a rational manner and thus achieve the highest benefit for available resources. In this study the cost-effectiveness of lamotrigine, vigabatrin and gabapentin was estimated by a cost minimization analysis for the first year of drug therapy using data based on published studies. In general, there was little difference between the initial direct costs of treatment, however, the fewer side-effects associated with gabapentin is reflected in the lower total costs of treatment in the first year resulting in savings of £18.52 per patient compared with lamotrigine and £47.18 compared with vigabatrin. Based on incidence data estimates this translates to estimated direct cost savings to the UK of between £166 680 and £424 620 per annum.
INTRODUCTION
The prevalence of active epilepsy in the United Kingdom (UK) is between 4-5/1000 ~'2. The total annual economic burden of epilepsy has been estimated at £1930m per annum, with £32m spent on antiepliepsy drug therapy alone 3. Despite the high level of expenditure on drug therapy for epilepsy there is little, if any, information regarding the relative cost-effectiveness of the available drug therapies.
Expenditure on any treatment or therapy means that these resources cannot be used elsewhere, therefore benefit is forgone from an alternative treatment. This is the notion of opportunity cost in economics 4. Therefore it is important to identify the most cost-effective forms of treatment in order to make the best use of available resources. There has recently been a rapid expansion in the number of new antiepileptic drugs (AEDs) to treat patients with intractable epilepsy with the introduction of vigabatrin, lamotrigine and gabapentin. These AEDs are emerging as the main adjunctive treatments for patients who have failed combinations of the more established antiepileptic drugs. Studies comparing the relative cost-effectiveness of the new AEDs will aid clinicians and health care planners to decide on their efficient utilization.
In order to pursue the objective of benefit maximization a means of evaluating both the costs and benefits associated with resources used is required. Economic evaluation compares the costs and outcomes enabling the relative merits of alternative uses of resources to be considered. In this study we carried out a cost minimization analysis to compare the relative costs of vigabatrin, lamotrigine, and gabapentin as add-on therapy in patients with intractable partial seizures. Cost-minimization analysis considers only the costs of interventions and requires that the interventions under consideration have equal effectiveness, usually measured in terms of medical outcomes or natural units of health output associated with the intervention. This enables us to consider the relative costs and effects of treatment and to provide results in terms of the potential cost savings associated with switching to the most cost-effective therapy.
METHOD
In the absence of head to head trials the available evidence on the effectiveness of lamotrigine, vigabatrin and gabapentin is inconclusive, that is there is significant overlap in the efficacy ranges such that they cannot be shown to differ 5-~7. On this basis we have assumed equal efficacy and therefore have undertaken a cost minimization analysis.
The target population in this study is patients with intractable partial epilepsy over the age of 12 years.
Costs fall into three broad areas; direct costs of therapy and costs of side-effects; indirect costs, such as production losses associated with illness; and intangible costs such as psychological costs of illness. In our main analysis we will concentrate on the direct costs of therapy and the treatment of side-effects in the first year of drug therapy. Data were not available in subsequent treatment years. We will consider indirect costs in a separate section but will not include them in the main results. Intangible costs were not measured.
There are several perspectives that can be taken when considering costs; society's, the public sector, the health service. Society's perspective suggests that all costs should be included regardless of upon which budget they fall. The health service perspective would only consider those costs which fall on the health service budget as relevant. We will only consider the costs that fall directly on the National Health Service (NHS) budget in our main analysis. Consequently our results will underestimate the full costs of treatment, nonetheless they give an indication of the financial implications to the NHS of the three therapies.
Costs were identified, where possible, from published or publicly available data. The costs used are presented in 1995 prices and are shown in Tables 1 and 2 .
There are three main tasks to enable the costs of the three therapies to be established. First, we need to identify the treatment pathways and side-effect profiles. Second, we need to quantify resource use associated with each pathway. Finally, we must attach costs to this resource use.
The treatment pathways were identified as far as possible with reference to standard practice ~8. These are shown in Tables 3 and 4 .
The side-effect profiles of each drug were estimated from published studies TM. The sideeffects were divided into minor and major side-effects. Minor side-effects were defined as those which did not lead to serious morbidity or mortality but did lead to general practitioner (GP) consultation in all cases and we estimated that this would lead to specialist referral in 1% of 19 . Major side-effects were defined as those which led to withdrawal from therapy. The effects of each major side-effect were extrapolated from published data 2°. The side effects and the assumptions used are summarized below.
Major side-effects with lamotrigine occur in 9-15% of patients 5'9-1L25. Fifty per cent of this number is due to poor seizure control. Of these, 5% may be admitted to hospital (5 days), requiring electroencephalography (EEG), computerized tomography (CT), and blood levels. The other 50-80% see a GP once, and 50-30% see a specialist once. Forty-five percent of these are for skin rashes. Of these, 4-5% may require admission to hospital (5 days), for blood level estimations. The other 50-80% see a GP once, and 30-50% see a specialist once. Five percent of the others see a GP (due to insomnia, headache, diplopia), and 0.5-1% see a specialist for CT, EEG, and blood levels.
Major side-effects of vigabatrin occur in 6-15% of patients 7"8'2~-23. Fifty per cent are behavioural disturbances. Of these, 50% require hospital admission (5 days), including EEG, CT, and blood levels of other AEDs. The other 50% of patients have other side-effects: mainly decreased consciousness and gastrointestinal reactions. Of Major side-effects with gabapentin occur in 3-7% of patients 6J2-15'24. All withdrawals are due to CNS side effects: somnolence, ataxia, dizziness, fatigue, nausea, or abnormal thinking. A GP consultation is required in 3-7%, and in 50%, a specialist consultation is necessary. Of these, 4-5% may require admission to hospital (5 days) to undergo CT, EEG, and blood levels.
The manufacturers' titration schedules were used for the dosage increments. The average daily doses were based on the most commonly prescribed average doses 26. These were 1200 mg for gabapentin, 200mg for lamotrigine, and 2000 mg for vigabatrin. The drug costs used are shown in Table 5 .
The indirect costs were calculated assuming labour force participation rate for individuals with epilepsy of 35% 27 and 72% 3. We assumed a participation rate of 53% which is the midpoint of the estimates. We took the average earnings from Department of Employment data as £326 per week 2s. This gave an adjusted daily wage of £34.88.
RESULTS

Direct costs
The unit costs of each of the treatments and interventions associated with treatment pathways and adverse events are presented in Tables 6-10 .
Of the three therapies vigabatrin is the least costly in terms of direct costs of therapy. However, when the costs of side-effects are taken into account gabapentin is the least costly, resulting in savings of £18.52 over lamotrigine and £47.18 over vigabatrin in the first year of use. The overall costs are shown in Table 11 .
Potential annual cost savings to the UK
The annual pool of patients with intractable epilepsy who are suitable for one of the new drugs has been estimated to be 9000 new patients per annum, with a backlog of 82 000 patients 29. The total financial cost savings to the NHS in the first year of treating new patients with gabapentin would be £166 680 over lamotrigine and £424 620 over vigabatrin per annum in the first year of use. If all the existing 82 000 patients with intractable epilepsy were treated with gabapentin this would lead to a saving of £1 518 640 over lamotrigine and £3 868 760 over vigabatrin.
Indirect costs
The indirect costs of treatment are production losses associated with the illness itself or resulting from treatment. We assumed that where hospitalization was required this would result in the same number of days lost production, i.e. if a five-day stay in hospital was required this would result in five lost working days. Therefore the estimates of indirect costs are conservative. The results are presented in Table 12 . * Costs calculated on the basis of incidence and probability of requiring treatment, t Non-specified, ~t Insomnia, headache, diplopia. If we alter the assumptions regarding the maintenance dosage level however the results appear less robust. If we take the lower and upper limits for the possible maintenance dose levels (lamotrigine ranging from 75 to 300mg, vigabatrin ranging from 1500 to 4000mg and gabapentin ranging from 1200 to 2400 mg), these give us a range of costs for lamotrigine of £805.97-£1517.82, vigabatrin of £910.82-£1786.94 and gabapentin from £1063.96-£1511.04. Lamotrigine appeared to be less costly at the lower end of the dosage levels and gabapentin at the higher end.
Sensitivity analysis
DISCUSSION
Our results suggest that there may be potential cost savings to the NHS if new patients with intractable partial epilepsy are initially treated with gabapentin rather than the other available We found that the indirect costs associated with the standard therapies were similar. However, this is not surprising as the standard treatment profiles are almost identical. As in the main analysis the main difference appeared in the indirect costs of side-effects, and with gabapentin the relatively low incidence of major side-effects requiring hospitalization and other costly interventions resulted in the indirect costs being low. The main reason for the higher cost of lamotrigine was the cost of anticonvulsant levels of phenytoin, carbamazepine and sodium valproate. These are required because of the interactions of lamotrigine with the these The cost estimates appear robust with respect to the assumptions regarding the incidence of side-effects, but less so if the dosage levels are altered. However, if dosage levels have an impact on effectiveness it is difficult to maintain the assumption of equal effectiveness and a more sophisticated cost-effectiveness analysis would be required.
It should also be stressed that the main assumption underpinning our findings is that gabapentin, lamotrigine and vigabatrin are of equal efficacy. This assumption is based on available evidence, however this evidence lacks any head to head trials. If it is demonstrated that one of these new drugs has superior efficacy this then would invalidate the findings of this study.
Furthermore we assumed that the time patients spent on each AED is equal. If, however, an AED was less effective then patients would take it for less time, reducing the total drug costs associated with treatment. Also, with some of the AEDs, the time taken to build up to the effective dosages range and decide upon efficacy may be different. A trial of gabapentin therapy could conceivably take less time than lamotrigine, for example, thus reducing the total cost of treatment with gabapentin since less drug would be consumed.
Finally, it is not clear whether these cost savings will continue after year one, most notably because many of the major side-effects will lead to withdrawal from the drug therapy and consequently the costs of these side-effects will not continue. It is probable that as gabapentin was associated with least side-effects in the first year that this would continue with more prolonged usage. However, this is only an assumption as long-term tolerability data is limited.
In conclusion, this paper is one of the first studies to investigate the cost-effectiveness of antiepilepsy drug therapy for partial intractable epilepsy. The main short comings to this study are the assumptions which have to be made when modelling treatment paths and side-effects rather than using actual patient data. The alternative approach to this method, which has been promoted ~, is to carry out economic analyses together with the clinical trials, but this carries large logistic and financial costs which are unlikely ever to be met by the existing AED development budgets. This study shows that the cost incurred by AEDs can still be adequately assessed by modelling, and that further studies to look at the relative cost-effectiveness of the 'new', and the more established AEDs, are needed to promote cost savings in the treatment of patients with refractory epilepsy.
